IQ-AI Ltd - London-based medical services company - US-based subsidiary Imaging Biometrics LLC says that US Food & Drug Administration has approved an expanded access programme for oral gallium maltolate. This EAP will run in parallel with the current phase 1 clinical trial being conducted at the Medical College of Wisconsin. Explains that ‘As the phase 1 trial concludes this fall and while the data is being compiled, eligible patients in the US will have the option of participating in the EAP.’
‘Providing eligible patients access to GaM as a potential treatment ahead of regulatory approval underscores our commitment to helping address a clear unmet patient need,’ says Trevor Brown, chief executive of IQ-AI.
Current stock price: 1.25 pence, up 4.6% in London on Tuesday
12-month change: down 54%
Copyright 2024 Alliance News Ltd. All Rights Reserved.
